Akero The First To Show Fibrosis Improvement In Cirrhotic MASH

 
• By Joseph Haas
  
Liver
Akero has the first MASH drug to show a fibrosis benefit in cirrhotic patients
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from Therapy Areas